Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

invendo medical GMBH

This article was originally published in Start Up

Executive Summary

invendo medical has crystallized its mission around solving not just the single issue of sedationless colonoscopy, which is regarded by some as the solution to getting more patients into the endoscopy suite for colorectal cancer screening, but all three of what the company characterizes as the major drawbacks of colonoscopy: 1) patient discomfort (triggering the costs and complications of sedation); 2) the ease-of-use issue, or rather, the challenging learning curve of conventional endoscopes; and 3) the reusability that leads to cumbersome cleaning routines and residual infection risk. Invendo has developed a non-push scope that drives itself under the operator's control.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel